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T he previous issue of Value in Health presentedseveral papers from the First General Session
of the ISPOR Lipid Conference on current clinical
understanding and controversies regarding choles-
terol, lipid therapy, and the cardiovascular disease
process. This issue provides papers and commen-
taries from the Second General Session, discussing
methodological issues in pharmacoeconomic as-
sessment and modeling of alternative lipid thera-
pies. Unfortunately, the earlier clinical controver-
sies did not go away. Moreover, since any two
economists will produce at least five different opin-
ions [1] (Mike Barnicle has made us more careful
about joke citations), new controversies were added
as the conference turned to lipid economics.
Assessment of lipid therapy outcomes and cost
effectiveness is inherently complex and uncertain.
This is in part because, thankfully, even high-risk
patients are not inevitable victims of cardiovas-
cular disease (CVD). Annual patient CVD risks of
1-2% are high enough to qualify for high-risk sta-
tus. This means that clinical trials would be too
large, too long, and too expensive to answer every
possible question on the relationship between
CVD disease risk, risk reduction with alternative
lipid therapies, and long-term clinical outcomes,
including quality-of-life changes and all-cause mor-
tality impacts. Lipid therapy means lifetime treat-
ment, but clinicians can't wait for a 50-year ran-
domized controlled clinical trial before deciding
whether a specific medication should be prescribed.
Thus, modeling is a necessary component of pro-
jecting the outcomes and the value of lipid ther-
apy. The key to valid and reliable modeling is the
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incorporation of plausible parameters based on
current understanding of the clinical and eco-
nomic impacts of treatment.
In the opening session presentation, Dr. Gerry
Oster [2] traces lipid pharmacoeconomics back two
decades to Berwick, Cretin, and Keeler's pioneering
evaluation of cholesterol intervention strategies for
children [3]. Oster points out that much of the
pharmacoeconomic literature has followed the Ber-
wick et al. methodology in crucial respects, includ-
ing: 1) the discounting of both expected future
costs and benefits by the same rate; 2) the early
adoption of life-years saved as a meaningful bene-
fits measure; 3) the lifetime projection of disease
risks and therapeutic risk reductions from epidemi-
ological cross-sectional risk equations estimated on
the Framingham Heart Study cohort [4]; and 4) the
ranking of relative cost-effectiveness of alternative
interventions for patients with varying risks, and
interventions with differing costs and targets.
Oster and Epstein published the first formal
pharmacoeconomic study in 1986 [5]. Building on
the basic structure of Berwick et al., Oster and
Epstein added important modeling components
that have substantially impacted subsequent phar-
macoeconomic literature. These include: 1) a link-
age of incidence-based cost-of-illness estimates to
Framingham risk functions; 2) the explicit consid-
eration of cost-effectiveness differences across pa-
tient risk profiles (e.g., smoking habit, diabetes,
hypertension, level of cholesterol, etc.}; 3) consid-
eration of the fraction of risk reduction benefits
predicted by Framingham equations that was ac-
tually achievable with lipid therapy; and 4) the
consideration of direct and indirect economic cost
perspectives.
Oster tours the subsequent literature, showing
how later pharmacoeconomic studies address cost-
effectiveness of lipid therapies in women, the eld-
erly, and those with preexisting coronary artery dis-
ease, how newer therapies-particularly statins-«
were assessed, how the CRIS [6] study was used to
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evaluate lipid therapy in actual clinical practice,
and how some of the clinical outcomes studies (e.g.,
45 [7] and W05COPS [8]) may impact earlier find-
ings. Oster concludes that this literature has held up
reasonably well. Probably the greatest accomplish-
ment of lipid pharmacoeconomics research has
been to establish the enormous difference in relative
cost-effectiveness between interventions that only
consider a patient's cholesterol level in isolation
and those that take into account other patient char-
acteristics that increase patient CVD risk levels.
The studies have consistently documented that,
while bile acid sequestrants are cost-effective for a
small group of very-high-risk patients, statins are
more broadly cost-effective in treating patients
meeting National Cholesterol Education Program
(NCEP) lipid treatment guidelines for primary and
secondary prevention [9]. In fact, the NCEP Adult
Treatment Panel has explicitly incorporated the
lipid pharmacoeconomic literature into its guide-
lines development process for the past decade-a
welcome sign that pharmacoeconomics has been
successfully moving from theory to practice even
before ISPOR made this a major focus.
Oster ends with a note of caution regarding
model building. Given cost and ethical issues, it is
unlikely that comprehensive outcomes studies will
ever be carried out on all lipid monotherapies and
combination therapies. While conceding the neces-
sity of modeling, he points out that" ... seemingly
unimportant differences in pharmacology may
yield significant differences in clinical outcomes."
His proposed solution is to use intermediate or
surrogate markers (e.g., reductions in low density
lipoprotein [LDL] cholesterol) in cost-effectiveness
analysis of drugs that do not have hard end-point
trials. Thus, one would not present cost/QALY re-
sults for an untested statin therapy, but only cost/%
LlLDL. The concern with this approach is that if
specific surrogate markers are imperfect measures
of ultimate therapeutic benefits, retreating to cost-
effectiveness analysis of surrogate markers may
not be helpful.
Dr. Susan Andrade's paper presents another
caution to those who build models of lipid phar-
macoeconomics for real-world decision-making
[10]. Most of the lipid therapy clinical trials have
been quite successful in maintaining high compli-
ance with drug therapy. This results from many
factors, including the self-selection of patients and
clinicians who are most likely to follow directions
and instructions into the complex clinical trial
study environment, and the repeated monitoring
of patients by clinical research personnel during a
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clinical trial. Patients in real-world practice are far
less compliant. As Andrade points out, even though
the I-year average discontinuation rate for niacin
therapy was 4% in clinical trials, it was 46% in
actual primary care clinical practice. This raises
two issues. First, clinicians and other decision-
makers are not interested in therapies that look
great in clinical trials but are not going to be used
by their own patients. Second, if efficacy and out-
comes are established in clinical trials, how does
one extrapolate the results of these trials to real-
world environments where patients may use only
a fraction of the drug that was used in the clinical
trials? How do different patterns of therapy non-
compliance affect patient outcomes? For example,
is missing one's lipid therapy every other day as
bad or worse than missing one's medication every
other month? A further policy problem results
from the fact that we also know very little about
what types of interventions (other than forcing pa-
tients in clinical trials) would significantly enhance
therapy compliance, and which of these compli-
ance interventions would be cost-effective.
Thomas Delea's paper follows up on Oster's
suggestion to use reductions in LDL cholesterol as
a surrogate marker for the efficacy of lipid therapy
[11]. A strong case has been made that therapeutic
changes in LDL cholesterol are the best measure
of drug efficacy [12J. If one accepts this view, then
lipid therapy cost-effectiveness simplifies substan-
tially. One does not need to evaluate the actual
outcomes effects of therapy on CVD event reduc-
tion and survival. One merely needs to consider
which therapy or therapeutic combination achieves
the greatest reduction in LDL for a given spending
level. Based on US pricing and treatment assump-
tions, Delea maps out the efficiency frontier for all
of the statins (except cerivastatin), as well as for
niacin, colestipol, and cholestyramine.
The Delea paper updates a methodology devel-
oped by Schulman et al. [13]. A concern with this
approach is that even when calculating costl%
LlLDL, the outcomes effects of lipid therapy cannot
really be ignored. A lipid therapy that is more effec-
tive in reducing CVD events will have more of its
treatment costs offset by reductions in avoided costs
for myocardial infarctions (MIs), percutaneous
transluminal coronary angioplasties (PTCAs), coro-
nary artery bypass grafts (CABGs), strokes, etc. A
drug that is more effectiveat reducing all-cause mor-
tality may actually cost more (everything else being
equal), since people living longer have to purchase
more of the medication. For many patients, these
cost and mortality avoidance effects may be small
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enough to ignore when calculating net costs of ther-
apy. Nevertheless, there are certain high-risk patients
where assumptions that are made about survival and
CVD event reduction outcomes could reverse the
cost-effectiveness analysis (CEA) rank orderings,
even within a cost/% ~LDL evaluation framework.
The paper by Kinosian and Glick addresses a
number of outstanding pharmacoeconomic mod-
eling concerns, including the extension of results
beyond clinical trials, as well as to elderly patients
(who are often underrepresented in clinical trials)
[14]. They discuss the importance of international
variation in CVD treatment patterns, patient risk
stratification, and the differences between primary
and secondary prevention. In contrast to Delea
[11], they argue that change in LDL cholesterol is
not the only (or even the most important) measure
of cholesterol risk and therapeutic efficacy. They
argue that the LDLIHDL ratio is a better measure
of baseline risk, and the change in the LDLIHDL
ratio is a better measure of the value of therapeu-
tic intervention than LDL alone. This was a view
that Dr. Castelli also presented in the previous
conference session [15]. A concern that Dr. Brown
raised regarding clinical application of the LDU
HDL ratio was that measurement errors, particu-
larly in measuring HDL, were fairly common in the
real world, and that small measurement errors
could have large effects on the LDUHDL ratio [16].
Hay's paper makes a plea for greater transpar-
ency in lipid pharmacoeconomic model building
and provides some methodological suggestions for
reducing opacity [17]. While the general modeling
themes and approaches described by Oster [2]
have been carried forward by most subsequent re-
searchers, slight differences in modeling assump-
tions and parameter values can have significant ef-
fects on results, particularly on the rank ordering
of the cost-effectiveness of alternative lipid thera-
pies. The simplest way to allow readers and users
of this literature to make comparisons across
models would be to make the data and models di-
rectly available to them (e.g., possibly through an
Internet website). Proprietary issues, adequacy of
documentation, and other concerns may make this
approach difficult to implement, at least in the
near future. Hay suggests that detailed multivari-
ate sensitivity analysis of model outcomes pro-
vided in the form of a regression equation allows
users and readers to determine both the sensitivity
of the model to specific parameter assumptions, as
well as to project model results to validate the as-
sumptions and calculations of a particular model
and apply it to their own circumstances.
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There is no longer controversy about whether
high cholesterol should be treated, either in primary
or secondary high-risk patients. The multiple risk
factor NCEP clinical treatment guidelines, with
their focus on LDL cholesterol as both a primary in-
dicator and goal for treatment, have tried to balance
simplicity and ease of clinician use against what is
known regarding the clinical benefits of therapy.
But simplicity can sometimes get in the way of accu-
racy. When decision-makers go beyond the question
of whether to treat lipids, to the question of which
lipid therapy is the most cost-effective, different
modeling assumptions, particularly those regarding
the' relationship between surrogate markers and
clinical outcomes, can have significant effects on rel-
ative cost-effectiveness rankings.
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